ATE516305T1 - Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten - Google Patents
Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonistenInfo
- Publication number
- ATE516305T1 ATE516305T1 AT05707720T AT05707720T ATE516305T1 AT E516305 T1 ATE516305 T1 AT E516305T1 AT 05707720 T AT05707720 T AT 05707720T AT 05707720 T AT05707720 T AT 05707720T AT E516305 T1 ATE516305 T1 AT E516305T1
- Authority
- AT
- Austria
- Prior art keywords
- ralpha
- agonists
- antagonists
- specific
- binding site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290542 | 2004-02-27 | ||
| PCT/EP2005/002367 WO2005085282A1 (en) | 2004-02-27 | 2005-02-10 | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516305T1 true ATE516305T1 (de) | 2011-07-15 |
Family
ID=34917212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05707720T ATE516305T1 (de) | 2004-02-27 | 2005-02-10 | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7858081B2 (de) |
| EP (1) | EP1718670B1 (de) |
| JP (3) | JP5744369B2 (de) |
| AT (1) | ATE516305T1 (de) |
| ES (1) | ES2367027T3 (de) |
| WO (1) | WO2005085282A1 (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085282A1 (en) * | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
| MXPA06013482A (es) | 2004-05-27 | 2007-03-01 | Crucell Holland Bv | Moleculas de enlace capaces de neutralizar el virus de la rabia y sus usos. |
| CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1777294A1 (de) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine |
| EP2251034B1 (de) | 2005-12-02 | 2018-02-14 | Icahn School of Medicine at Mount Sinai | Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung |
| US9303080B2 (en) | 2006-01-13 | 2016-04-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| AU2013273643C1 (en) * | 2007-05-11 | 2016-08-11 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| WO2008143794A1 (en) | 2007-05-11 | 2008-11-27 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| CA2691785C (en) | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| CU23716A1 (es) * | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| WO2011031986A1 (en) | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Assays for soluble il-15 receptor alpha |
| KR20120093163A (ko) * | 2009-09-14 | 2012-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| EP2619229B1 (de) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Lösliche, multimere il-15- fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung |
| EP2537933A1 (de) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine |
| ES2747997T3 (es) | 2012-10-24 | 2020-03-12 | Novartis Ag | Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa |
| CN105188746B (zh) | 2013-03-14 | 2020-03-17 | 西奈山伊坎医学院 | 新城疫病毒及其用途 |
| KR20150145260A (ko) | 2013-04-19 | 2015-12-29 | 싸이튠 파마 | 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료 |
| WO2014207173A1 (en) * | 2013-06-27 | 2014-12-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases |
| PT3030575T (pt) | 2013-08-08 | 2018-10-31 | Univ Paris Descartes | Modulocinas baseadas em il-15 e no domínio sushi de il-15rα |
| WO2015018529A1 (en) | 2013-08-08 | 2015-02-12 | Cytune Pharma | Combined pharmaceutical composition |
| ES2904276T3 (es) | 2013-09-27 | 2022-04-04 | Massachusetts Inst Technology | Nanoestructuras de proteínas biológicamente activas sin vehículo |
| WO2015103928A1 (zh) | 2014-01-08 | 2015-07-16 | 上海恒瑞医药有限公司 | Il-15异源二聚体蛋白及其用途 |
| EP3441084A1 (de) | 2014-02-27 | 2019-02-13 | Viralytics Limited | Onkolytisches virus und immunstimulator zur kombinationsbehandlung von krebs |
| EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
| EP3160498B1 (de) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-basierte moleküle und verfahren zur verwendung davon |
| ES2811974T3 (es) | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
| CN107001438A (zh) * | 2014-10-14 | 2017-08-01 | 阿尔莫生物科技股份有限公司 | 白细胞介素‑15组合物及其用途 |
| EP3064507A1 (de) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon |
| CA3007819A1 (en) * | 2015-12-21 | 2017-06-29 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| EP3468581A1 (de) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| RU2019114175A (ru) * | 2016-10-14 | 2020-11-16 | Ксенкор, Инк. | Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1 |
| JP7492336B2 (ja) | 2016-10-21 | 2024-05-29 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ－１５に基づく分子 |
| CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2018229706A1 (en) * | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| JP2020524167A (ja) | 2017-06-20 | 2020-08-13 | ナントクエスト インコーポレイテッド | Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法 |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| EP3678701A4 (de) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| KR20200127207A (ko) * | 2018-02-26 | 2020-11-10 | 신톡스, 인크. | Il-15 접합체 및 이의 용도 |
| TWI776024B (zh) | 2018-02-28 | 2022-09-01 | 美商輝瑞大藥廠 | Il-15變體及其用途 |
| MA52662A (fr) * | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Div A/S | Conjugués d'il-2 |
| JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| KR20210003814A (ko) * | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| MA52289A (fr) * | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| JP7477885B2 (ja) | 2018-06-22 | 2024-05-02 | キュージーン インコーポレイテッド | サイトカインをベースとした生理活性化薬剤およびその使用方法 |
| MX2021004059A (es) | 2018-10-12 | 2021-09-23 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| WO2020234387A1 (en) | 2019-05-20 | 2020-11-26 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
| JP2022536898A (ja) | 2019-06-12 | 2022-08-22 | アスクジーン・ファーマ・インコーポレイテッド | 新規ｉｌ－１５プロドラッグおよびその使用方法 |
| CN113646328B (zh) | 2019-08-19 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | 一种免疫细胞因子及其制备与用途 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| US20210188933A1 (en) * | 2019-12-18 | 2021-06-24 | Nantcell, Inc | Methods of treating pancytopenia |
| WO2021142476A1 (en) | 2020-01-12 | 2021-07-15 | Dragonfly Therapeutics, Inc. | Single-chain polypeptides |
| CN118598977A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| CA3195276A1 (en) | 2020-10-26 | 2022-05-05 | Stefano FERRARA | Il-2/il-15rb?? agonist for treating non-melanoma skin cancer |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| AU2022299404A1 (en) | 2021-06-23 | 2023-12-07 | Cytune Pharma | Interleukin 15 variants |
| AU2022325498A1 (en) | 2021-08-13 | 2024-02-01 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024170555A1 (en) | 2023-02-14 | 2024-08-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Il-15 fusion proteins with improved properties |
| WO2024216170A2 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552303A (en) * | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| ATE298367T1 (de) * | 1996-04-26 | 2005-07-15 | Beth Israel Hospital | Interleukin-15 antagoniste |
| US6451308B1 (en) * | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| WO2005085282A1 (en) * | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
-
2005
- 2005-02-10 WO PCT/EP2005/002367 patent/WO2005085282A1/en active Application Filing
- 2005-02-10 AT AT05707720T patent/ATE516305T1/de not_active IP Right Cessation
- 2005-02-10 JP JP2007500188A patent/JP5744369B2/ja not_active Expired - Fee Related
- 2005-02-10 US US10/590,734 patent/US7858081B2/en not_active Expired - Fee Related
- 2005-02-10 ES ES05707720T patent/ES2367027T3/es not_active Expired - Lifetime
- 2005-02-10 EP EP05707720A patent/EP1718670B1/de not_active Expired - Lifetime
-
2010
- 2010-12-23 US US12/978,115 patent/US9493533B2/en not_active Expired - Fee Related
-
2012
- 2012-12-28 JP JP2012287740A patent/JP5819281B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-02 JP JP2015133396A patent/JP2015214561A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1718670B1 (de) | 2011-07-13 |
| JP2013081472A (ja) | 2013-05-09 |
| JP2007528726A (ja) | 2007-10-18 |
| EP1718670A1 (de) | 2006-11-08 |
| US9493533B2 (en) | 2016-11-15 |
| US20080255039A1 (en) | 2008-10-16 |
| US20110158938A1 (en) | 2011-06-30 |
| JP5819281B2 (ja) | 2015-11-24 |
| JP2015214561A (ja) | 2015-12-03 |
| US7858081B2 (en) | 2010-12-28 |
| JP5744369B2 (ja) | 2015-07-08 |
| ES2367027T3 (es) | 2011-10-27 |
| WO2005085282A1 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516305T1 (de) | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten | |
| ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
| CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| MY138267A (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
| DE60220719D1 (de) | Antikörper gegen das muc18-antigen | |
| MA29663B1 (fr) | Modification du facteur fviii en fonction du site | |
| DE69940063D1 (de) | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin | |
| BRPI0412537A (pt) | antagonista do receptor muscarìnico da acetilcolina | |
| CO5460266A1 (es) | Novedosos analogos de la somatostatina | |
| DE60236212D1 (de) | Neue isoform des gefässendothelzell wachstumshemmers (vegi) | |
| MX2021015651A (es) | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). | |
| DE602004012763D1 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
| UA87122C2 (ru) | Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения | |
| ATE386050T1 (de) | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden | |
| CY1108643T1 (el) | Κυτταρικη σειρα και χρησεις της | |
| DE60326430D1 (de) | Varianten von säugerprolactin | |
| DE60036469D1 (de) | 17867, eine menschliche aminopeptidase | |
| WO2002007676A3 (en) | Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) | |
| EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
| ATE374786T1 (de) | Agonisten und antagonisten von urotensin-ii | |
| WO2004003133A8 (en) | Pain signaling molecules | |
| BRPI0416154A (pt) | combinação de antagonistas t1, amilorida ou triamterina, e um diurético |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |